These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 26867766)

  • 21. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
    Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X
    Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced antitumor effects of the BRBP1 compound peptide BRBP1-TAT-KLA on human brain metastatic breast cancer.
    Fu B; Long W; Zhang Y; Zhang A; Miao F; Shen Y; Pan N; Gan G; Nie F; He Y; Zhang J; Teng G
    Sci Rep; 2015 Jan; 5():8029. PubMed ID: 25619721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zerumbone Induces Apoptosis in Breast Cancer Cells by Targeting αvβ3 Integrin upon Co-Administration with TP5-iRGD Peptide.
    E M Eid E; S Alanazi A; Koosha S; A Alrasheedy A; Azam F; M Taban I; Khalilullah H; Sadiq Al-Qubaisi M; A Alshawsh M
    Molecules; 2019 Jul; 24(14):. PubMed ID: 31337024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer.
    Yang J; Yang J; Wei Y; Yin H; Fang L; Chai D; Li H; Li H; Zhang Q; Zheng J
    Int Immunopharmacol; 2019 May; 70():125-134. PubMed ID: 30798161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Superior intratumoral penetration of paclitaxel nanodots strengthens tumor restriction and metastasis prevention.
    Ni D; Ding H; Liu S; Yue H; Bao Y; Wang Z; Su Z; Wei W; Ma G
    Small; 2015 Jun; 11(21):2518-26. PubMed ID: 25678130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells.
    Gu G; Gao X; Hu Q; Kang T; Liu Z; Jiang M; Miao D; Song Q; Yao L; Tu Y; Pang Z; Chen H; Jiang X; Chen J
    Biomaterials; 2013 Jul; 34(21):5138-48. PubMed ID: 23582684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Shrapnel nanoparticles loading docetaxel inhibit metastasis and growth of breast cancer.
    Xu P; Meng Q; Sun H; Yin Q; Yu H; Zhang Z; Cao M; Zhang Y; Li Y
    Biomaterials; 2015 Sep; 64():10-20. PubMed ID: 26106797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery.
    Ma L; Chen Q; Ma P; Han MK; Xu Z; Kang Y; Xiao B; Merlin D
    Nanomedicine (Lond); 2017 Aug; 12(16):1991-2006. PubMed ID: 28745123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An iRGD peptide fused superantigen mutant induced tumor-targeting and T lymphocyte infiltrating in cancer immunotherapy.
    Song Y; Xu M; Li Y; Li Y; Gu W; Halimu G; Fu X; Zhang H; Zhang C
    Int J Pharm; 2020 Aug; 586():119498. PubMed ID: 32505575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antitumor and antimetastatic effect of antimicrobial peptide conjugated with tumor homing peptide TMTP1 on the transplanted prostate cancer and gastric cancer in nude mice].
    Ma XY; Li S; Luo DF; Liu RH; Lu YP; Wang SX; Ma D; Xi L
    Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):737-41. PubMed ID: 24378093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability.
    Gao F; Zhang J; Fu C; Xie X; Peng F; You J; Tang H; Wang Z; Li P; Chen J
    Int J Nanomedicine; 2017; 12():4147-4162. PubMed ID: 28615942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A modified thymosin alpha 1 inhibits the growth of breast cancer both in vitro and in vivo: suppressment of cell proliferation, inducible cell apoptosis and enhancement of targeted anticancer effects.
    Lao X; Li B; Liu M; Shen C; Yu T; Gao X; Zheng H
    Apoptosis; 2015 Oct; 20(10):1307-20. PubMed ID: 26283169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased antitumor activity of tumor-specific peptide modified thymopentin.
    Lao X; Li B; Liu M; Chen J; Gao X; Zheng H
    Biochimie; 2014 Dec; 107 Pt B():277-85. PubMed ID: 25236717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
    Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
    Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL?
    Zhang WQ; Yu KF; Zhong T; Luo LM; Du R; Ren W; Huang D; Song P; Li D; Zhao Y; Wang C; Zhang X
    J Drug Target; 2015 Dec; 23(10):897-909. PubMed ID: 26087869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer.
    Wang F; Li B; Fu P; Li Q; Zheng H; Lao X
    Int J Pharm; 2018 Aug; 547(1-2):611-620. PubMed ID: 29933059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor homing cell penetrating peptide decorated nanoparticles used for enhancing tumor targeting delivery and therapy.
    Gao H; Zhang Q; Yang Y; Jiang X; He Q
    Int J Pharm; 2015 Jan; 478(1):240-250. PubMed ID: 25448586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells.
    Zhang L; Xing Y; Gao Q; Sun X; Zhang D; Cao G
    Biomed Pharmacother; 2017 Sep; 93():1136-1143. PubMed ID: 28738522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain.
    Hamilton AM; Aidoudi-Ahmed S; Sharma S; Kotamraju VR; Foster PJ; Sugahara KN; Ruoslahti E; Rutt BK
    J Mol Med (Berl); 2015 Sep; 93(9):991-1001. PubMed ID: 25869026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. iRGD as a tumor‑penetrating peptide for cancer therapy (Review).
    Yin H; Yang J; Zhang Q; Yang J; Wang H; Xu J; Zheng J
    Mol Med Rep; 2017 May; 15(5):2925-2930. PubMed ID: 28358432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.